Xiaomo: Hanson Pharmaceuticals (03692) maintains a positive “increase” rating in lung cancer treatment data targeting B7-H3 ADC products

The Zhitong Finance App learned that J.P. Morgan released a research report saying that Ris-Rez, a targeted B7-H3 antibody-conjugated drug (ADC) developed by Hanson Pharmaceuticals (03692), recently released the latest research data. The overall survival (OS) results in treating second-line recurrent small cell lung cancer (2L SCLC) were positive, and TAM-Peli, a targeted B7-H3 ADC product independently developed by Yilian Biotech. Among them, Ris-Rez has a significantly longer median OS, and Tam-Peli is likely to be safer Excellent. The bank maintains Hanson Pharmaceuticals' “gain” rating with a target price of HK$50. It predicts that its innovative drug sales and licensing revenue will drive the compound annual growth rates of revenue and profit of 12% and 15% respectively from 2020 to 2030. Potential future catalysts include commercial drug sales, readout of key asset data and additional external licensing transactions.